75A50122C00065↗

Name: 75A50122C00065: Treatment for Use in a Mass Casualty Event Where Thrombocytopenia or Platelet Loss Is a Major Concern.
Creator: SpendQuery
License: https://www.usa.gov/government-works

Amgen USA Inc received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $549.82M obligated so far for health r&d services; health care services; experimental development. It runs to 2032-09-29.

Key facts · data as of Oct 21, 2026

Recipient: Amgen USA Inc
Awarding agency: Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
Contracting office: Barda - Aspr / Daappo / Barda Dcma (75A501)
Obligated to date: $549.82M
Potential value: $982.69M
Ends: 2032-09-29

Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 21, 2026.

Cite this page: SpendQuery, Award 75A50122C00065, data as of Oct 21, 2026, https://spendquery.com/award?id=CONT_AWD_75A50122C00065_7505_-NONE-_-NONE-

Amgen USA Inc: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys

TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.

Definitive Contract · Office of Assistant Secretary for Preparedness and Response · to Amgen USA Inc (UEI XPGNQMXHP493) · data as of 2026-10-21

Obligated to date$549.82M8 actions

Current value$839.88Mwith options exercised

Potential value$982.69Mif every option is used

Period2022-09-30 → 2032-09-29current end date

What it is

Product or service: Health R&D Services; Health Care Services; Experimental Development (PSC AN13)
Industry: Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
Contracting office: Barda - Aspr / Daappo / Barda Dcma (75A501)
Competition: Full and open competition · 1 offer received
Pricing: Firm fixed price
How it was bought: Standalone contract
Solicitation: 75A50122R00021
Where the work is: Ventura, CA · district CA-26

Obligations by fiscal year

FY2023$204.86M

FY2024$129.00M

FY2025$89.98M

FY2026$125.99M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

8 actions since 2022-12-12. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2026-08-04	P00008	Supplemental agreement (work within scope)	$66.00M	EO14398 FOR FAR 52.222-90, UPDATED HHSAR AND EXERCISE OPTION PERIOD 4A FOR $65,698,998.00
2026-03-06	P00007	Supplemental agreement (work within scope)	$59.99M	EXERCISE OPTION PERIOD 4 AND MODIFY THE NUMBER OF DOSES. CHANGE THE PERIOD OF PERFORMANCE TO MARCH 4, 2026 THROUGH SEPTEMBER 29, 2032. THE TOTAL CONTRACT FUNDED VALUE INCREASED FROM $713,890,168.42 BY $59,988,838.10 TO $773,879,006.52.
2025-07-15	P00006	Option exercised	$89.98M	EXERCISE OPTION PERIOD 3 CLINS 0010, 0011, AND 0012.
2024-09-27	P00005	Administrative change	$0	REVISE OPTION PERIOD 2 CLINS 0007 - 0009 PERIOD OF PERFORMANCE.
2024-09-18	P00004	Funding only	$129.00M	EXERCISE OPTION PERIOD 2 CLINS 0007 - 0009 FOR THE PROCUREMENT OF 62,896 UNITS OF NPLATE PHARMACEUTICAL PRODUCTS.
2024-02-05	P00003	Administrative change	$0	NO COST MODIFICATION TO REVISE SECTION B.2.2, CLIN TABLE DESCRIPTION COLUMN FOR CLIN0005.
2023-09-20	P00002	Option exercised	$204.86M	AMGEN - EXERCISE OPTIONAL CLINS 0004, 0005, AND 0006. ADD FAR CLAUSE 52.204-27.
2022-12-12	P00001	Administrative change	$0	AMGEN - UNILATERAL MODIFICATION TO REVISE THE CONTRACTING OFFICER.

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗

Putting the award page together from the records…